ArticleAllergy2017
Dysregulation of interleukin 5 expression in familial eosinophilia.
Article in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00091871 (A Longitudinal Study of Familial Hypereosinophilia), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet journal of rare diseases · 2023Guideline
- The multidisciplinary approach to eosinophilia.Frontiers in oncology · 2023Review
- Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.Allergy · 2023Review
- Eosinophil-mediated inflammation in the absence of eosinophilia.Asia Pacific allergy · 2021Review
- Contributions of Eosinophils to Human Health and Disease.Annual review of pathology · 2020Review
- Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights.Journal of asthma and allergy · 2020Review
- Approach to Patients with Eosinophilia.The Medical clinics of North America · 2020Review
- Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care.Allergy · 2019Review
- Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.Current hematologic malignancy reports · 2018Review
- Biologic Agents for the Treatment of Hypereosinophilic Syndromes.The journal of allergy and clinical immunology. In practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundFamilial eosinophilia (FE) is a rare autosomal dominant inherited disorder characterized by the presence of lifelong peripheral eosinophilia (>1500/μL). Mapped to chromosome 5q31-q33, the genetic cause of FE is unknown, and prior studies have failed to demonstrate a primary abnormality in the eosinophil lineage.
objectiveThe aim of this study was to identify the cells driving the eosinophilia in FE.
methodsMicroarray analysis and real-time PCR were used to examine transcriptional differences in peripheral blood mononuclear cells (PBMC), and in purified cell subsets from affected and unaffected family members belonging to a single large kindred. Cytokine levels in serum and PBMC culture supernatants were assessed by suspension array multiplexed immunoassays.
resultsWhereas IL-5 mRNA expression was significantly increased in freshly isolated PBMC from affected family members, this was not accompanied by increased mRNA expression of other Th2 cytokines (IL-4 or IL-13). Serum levels of IL-5 and IL-5 receptor α, but not IgE, were similarly increased in affected family members. Of note, IL-5 mRNA expression was significantly increased in purified CD3+ CD4+, CD14+, CD19+, and ILC2 cells from affected family members, as were IL-5 protein levels in supernatants from both stimulated PBMC and ILC2 cultures.
conclusionsThese data are consistent with the hypothesis that the eosinophilia in FE is secondary to dysregulation of IL-5 production in PBMC (and their component subsets).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.